Diagnostic imaging of the prostate cancer;Diagnostyka obrazowa raka gruczołu krokowego

Polski Merkuriusz Lekarski

Volumn 33, Issue 198, 2012, Pages 357-363

  Mocarska, Agnieszka ^a   Starosławska, Elzbieta ^a   Zelazowska Cieślińska, Iwonna ^a   Brzozowska, Anna ^a   Łosicki, Marek ^a   Stasiewicz, Dominika ^a   Burdan, Franciszek ^a  

^a St John's Cancer Centre   (Poland)

Author keywords

Magnetic resonance; Neoplasm diagnosis; Neoplasm staging; Prostatic cancer; Transrectal ultrasound

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

BIOPSY; DIAGNOSTIC IMAGING; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; MALE; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROSTATE TUMOR; REVIEW; TUMOR RECURRENCE;

BIOPSY; DIAGNOSTIC IMAGING; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; ULTRASOUND, HIGH-INTENSITY FOCUSED, TRANSRECTAL;

EID: 84873125809     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Benchikh El Fegoun A., Villersa A., Moreaub J.L.: PSA et suivi apres traitement du cancer de la prostate PSA and follow-up after treatment of prostate cancer. Prog. Urolog., 2008; 18; 137-144.
2. Berthelet E., Liu M., Truong P., et al.: CT slice index and thickness: Impact on organ contouring in radiation treatment planning for prostate cancer. J. Apel. Clin. Med. Physic., 2003; 4; 365-373.
3. Brett A.S., Ablin R.J.: Prostate-cancer screening - what the U.S. preventive services task force left out. N. Engl. J. Med., 2011; 365; 1949-1951.
4. Carroll P.R., Coakley F.V., Kurhanewicz J.: Magnetic resonance imaging and spectroscopy of prostate cancer. Rev. Urol., 2006; 8 (Suppl 1); 4-10.
5. Chu D.I., De Nunzio C., Gerber L., et al.: Predictive value of digital rectal examination for prostate cancer detection is modified by obesity. Prostate Cancer Prostatic Dis. 2011; 14; 346-353.
6. Cornud F., Lecouvet F., Portalez D., et al.: IRM et cancer de la prostate. J. Radiol. 2009
7. Cornud F., Lecouvet F., Portalez D.: Impact de l'IRM sur la prise en charge d'un cancer de prostate. Prog. FMC., 2010; 20; E13-E20.
8. Dhingsa R., Qayyum A., Coakley F.V.: Prostate cancer localization with endorectal MR imaging and MR spectroscopic imaging: Effect of clinical data on reader accuracy. Radiology., 2004; 230; 215-220.
9. Didkowska J., Wojciechowska U., Zatoński W.: Nowotwory złośliwe w Polsce w 2009 roku. Warszawa 2011; Centrum Onkologii Instytut im. M. Skłodowskiej-Curie; 44-45.
10. Engelhard K., Hollenbach H.P., Kiefer B., et al.: Prostate biopsy in the supine position in a standard 1.5-T scanner under real time MR-imaging control using a MR-compatible endorectal biopsy device. Eur. Radiol., 2006; 16; 1237-1243.
11. Franiel T., Lüdemann L., Birgit Rudolph B., et al.: Differentiation of prostate cancer from normal prostate tissue: Role of hotspots in pharmacokinetic MRI and histologic evaluation. Am. J. Roentgenol., 2010; 194; 675-681.
12. Franiel T., Stephan C., Erbersdobler A., et al.: Areas suspicious for prostate cancer: MR-guided biopsy in patients with at least one transrectal US-guided biopsy with a negative finding - multiparametric MR imaging for detection and biopsy planning. Radiology, 2011; 259; 162-172.
13. Giannarini G., Nguyen D.P., Thalmann G.T., et al.: Diffusion-weighted magnetic resonance imaging detects local recurrence after radical prostatectomy: Initial experience. Eur. Urolol., 2012; 61; e13-e22.
14. Goudarzi B., Kishimoto R., Komatsu S., et al.: Detection of bone metastases using diffusion weighted magnetic resonance imaging: comparison with (11)C-methionine PET and bone scintigraphy. Magn. Reson. Imaging 2010; 28; 372-379.
15. Halpern E.J.: Contrast-enhanced ultrasound imaging of prostate cancer. Rev. Urol., 2006; 8 (Suppl 1); S29-S37.
16. Hamilton W., Sharp D.: Symptomatic diagnosis of prostate cancer in primary care: a structured review. Br. J. Gen. Pract., 2004; 54; 617-621.
17. Hawkins T., Halewood M.M.: Technical note: identifying the prostate cancer 'superscan' by quantitative skeletal scintigraphy. Nucl. Med. Commun. 2008; 29; 654-659.
18. Heidenreich A.: Consensus criteria for the use of magnetic resonance imaging in the diagnosis and staging of prostate cancer: Not ready for routine use. Eur. Radiol., 2011; 59; 495-497.
19. Hoffelt S.Ch., Marschal Y. L., Garzotto M., et al.: A comparison of CT scan to transrectal ultrasound measured prostate volume in untread prostate cancer. Int. J. Radiation Oncology Biol. Phys., 2003; 57; 29-32.
20. Kanikowski M., Skowronek J., Milecki P., i wsp.: Brachyterapia HDR raka gruczołu krokowego. Urol. Pol., 2007; 60; 5-11.
21. Ketelsen D., Röthke M., Aschoff P., et al.: Detection of bone metastasis of prostate cancer - comparison of whole-body MRI and bone scintigraph. Rofo., 2008; 180; 746-752.
22. Kiliçkesmez Ö., Cimilli T., Inci E., et al.: Diffusion-weighted MRI of urinary bladder and prostate cancers. Diagn. Interv. Radiol., 2009; 15; 104-110.
23. Korporaal.G., Van den Berg C. AT., Jeukens C, at al.: Dynamic contrastenhanced CT for prostate cancer: relationship between image noise, voxel size, and repeatability, Radiology., 2010; 256; 976-984.
24. Low R.N., Fuller D.B., Muradyan N.: Dynamic gadolinium-enhanced perfusion MRI of prostate cancer: assessment of response to hypofractionated robotic stereotactic body radiation therapy. Am. J. Roentgenol., 2011; 197; 907-915.
25. Messiou Ch., Cooka G., Reid A.H.M., et al.: The CT flare response of metastatic bone disease in prostate cancer. Acta Radiol., 2011; 5; 557-561.
26. Picchio M., Crivellaro C., Giovacchini G., et al.: PET-CT for treatment planning in prostate cancer. Q. J. Nuc. Med. Mol. Imag., 2009; 53; 245-268.
27. Schlemmer H.P.: Multiparametric MRI of the prostate: method for early detection of prostate cancer? Rofo., 2010; 182; 1067-1075.
28. Skanjeti A., Pelosi E.; Lymph node staging with choline PET/CT in patients with prostate cancer: a review. ISRN Oncol., 2011; 2011; 219064.
29. Somford, D.M., Hambrock T., Hulsbergen van de Kaa C.A., et al.: Nitial experience with identifying high-grade prostate cancer using diffusionweighted MR imaging (DWI) in patients with a Gleason score -3 + 3 = 6 upon schematic TRUS-guided biopsy: A radical prostatectomy correlated series. Invest. Radiol., 2012; 47; 153-158.
30. Steiner C., Vess H., Zaidi H., et al.: Three-phase 18F-fluorocholine PET/ CT in the evaluation of prostate cancer recurrence. Nuklearmedicin, 2009; 48; 1-9.
31. Stephan C., Jung K., Soosaipillai A., at al.: Clinical utility of human glandular kallikrein 2 within a neural network for prostate cancer detection. BJU Int., 2005; 22, 521-527.
32. Vilanova J.C., Comet, J., Garcia-Figueiras A.: A utilidad de la resonancia magnética en el cáncer de prostata. Radiologia. 2010; 52; 513-524.
33. Von Knobloch R., Weber J., Varga Z., et al.: Bilateral fine-needle administered local anaesthetic nerve block for pain control during TRUS-guided multi-core prostate biopsy: A prospective randomised trial. Eur. Urol., 2002; 5; 483-580.
34. Yoshizako T., Wada A., Hayashi T., et al.: Usefulness of diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of prostate transition-zone cancer. Acta Radiol., 2008; 49; 1207-1213.